Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications

A Mayo Clinic study published in Annals of Surgery finds that metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 weight-loss medications in people with obesity. The research compared both treatment approaches and evaluated their effects on overall cardiovascular disease risk. While both interventions improve heart health in patients with obesity, the surgical approach demonstrated superior long-term benefits. The findings have implications for treatment decisions in obesity care, highlighting the comparative effectiveness of surgical versus pharmaceutical interventions for cardiovascular protection.

Comparative Effectiveness of Bariatric Surgery vs. GLP-1 Medications

• ▪Both metabolic and bariatric surgery and GLP-1 medications improve cardiovascular health in people with obesity.
• ▪A Mayo Clinic study compared metabolic and bariatric surgery to GLP-1 medications as obesity treatments.
• ▪The Mayo Clinic study evaluated how metabolic and bariatric surgery and GLP-1 medications each affect overall risk of cardiovascular disease.
• ▪The Mayo Clinic study comparing bariatric surgery to GLP-1 medications for obesity is published in Annals of Surgery.

Long-Term Cardiovascular Risk Reduction Outcomes

• ▪Metabolic and bariatric surgery was associated with significantly greater reductions in long-term cardiovascular risk compared to GLP-1 medications.

Perspective of Bariatric surgery advocates

• ▪The Mayo Clinic study provides evidence that metabolic and bariatric surgery offers superior long-term cardiovascular protection compared to pharmaceutical weight-loss interventions.
• ▪Metabolic and bariatric surgery should be considered a primary treatment option for patients with obesity seeking cardiovascular risk reduction.

Perspective of GLP-1 medication manufacturers and prescribers

• ▪GLP-1 medications provide cardiovascular health improvements for people with obesity without requiring invasive surgical procedures.
• ▪GLP-1 medications offer a more accessible treatment option for obesity compared to metabolic and bariatric surgery.
• ▪The Mayo Clinic study confirms that GLP-1 medications deliver meaningful cardiovascular benefits for patients with obesity.

1 source